228 related articles for article (PubMed ID: 25238276)
1. Phase I/II study of intrapleural administration of a serotype rh.10 replication-deficient adeno-associated virus gene transfer vector expressing the human α1-antitrypsin cDNA to individuals with α1-antitrypsin deficiency.
Chiuchiolo MJ; Kaminsky SM; Sondhi D; Mancenido D; Hollmann C; Crystal RG
Hum Gene Ther Clin Dev; 2014 Sep; 25(3):112-33. PubMed ID: 25238276
[No Abstract] [Full Text] [Related]
2. Intrapleural administration of an AAVrh.10 vector coding for human α1-antitrypsin for the treatment of α1-antitrypsin deficiency.
Chiuchiolo MJ; Kaminsky SM; Sondhi D; Hackett NR; Rosenberg JB; Frenk EZ; Hwang Y; Van de Graaf BG; Hutt JA; Wang G; Benson J; Crystal RG
Hum Gene Ther Clin Dev; 2013 Dec; 24(4):161-73. PubMed ID: 24191907
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alphal-antitrypsin (AAT) vector in AAT-deficient adults.
Brantly ML; Spencer LT; Humphries M; Conlon TJ; Spencer CT; Poirier A; Garlington W; Baker D; Song S; Berns KI; Muzyczka N; Snyder RO; Byrne BJ; Flotte TR
Hum Gene Ther; 2006 Dec; 17(12):1177-86. PubMed ID: 17115945
[TBL] [Abstract][Full Text] [Related]
4. Intrapleural administration of a serotype 5 adeno-associated virus coding for alpha1-antitrypsin mediates persistent, high lung and serum levels of alpha1-antitrypsin.
De B; Heguy A; Leopold PL; Wasif N; Korst RJ; Hackett NR; Crystal RG
Mol Ther; 2004 Dec; 10(6):1003-10. PubMed ID: 15564132
[TBL] [Abstract][Full Text] [Related]
5. High levels of persistent expression of alpha1-antitrypsin mediated by the nonhuman primate serotype rh.10 adeno-associated virus despite preexisting immunity to common human adeno-associated viruses.
De BP; Heguy A; Hackett NR; Ferris B; Leopold PL; Lee J; Pierre L; Gao G; Wilson JM; Crystal RG
Mol Ther; 2006 Jan; 13(1):67-76. PubMed ID: 16260185
[TBL] [Abstract][Full Text] [Related]
6. 5 Year Expression and Neutrophil Defect Repair after Gene Therapy in Alpha-1 Antitrypsin Deficiency.
Mueller C; Gernoux G; Gruntman AM; Borel F; Reeves EP; Calcedo R; Rouhani FN; Yachnis A; Humphries M; Campbell-Thompson M; Messina L; Chulay JD; Trapnell B; Wilson JM; McElvaney NG; Flotte TR
Mol Ther; 2017 Jun; 25(6):1387-1394. PubMed ID: 28408179
[TBL] [Abstract][Full Text] [Related]
7. Expression of human alpha1-antitrypsin in mice and dogs following AAV6 vector-mediated gene transfer to the lungs.
Halbert CL; Madtes DK; Vaughan AE; Wang Z; Storb R; Tapscott SJ; Miller AD
Mol Ther; 2010 Jun; 18(6):1165-72. PubMed ID: 20372105
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of intramuscular injection of a recombinant adeno-associated virus alpha 1-antitrypsin (rAAV2-CB-hAAT) gene vector to AAT-deficient adults.
Flotte TR; Brantly ML; Spencer LT; Byrne BJ; Spencer CT; Baker DJ; Humphries M
Hum Gene Ther; 2004 Jan; 15(1):93-128. PubMed ID: 14965381
[TBL] [Abstract][Full Text] [Related]
9. Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing α1-antitrypsin: interim results.
Flotte TR; Trapnell BC; Humphries M; Carey B; Calcedo R; Rouhani F; Campbell-Thompson M; Yachnis AT; Sandhaus RA; McElvaney NG; Mueller C; Messina LM; Wilson JM; Brantly M; Knop DR; Ye GJ; Chulay JD
Hum Gene Ther; 2011 Oct; 22(10):1239-47. PubMed ID: 21609134
[TBL] [Abstract][Full Text] [Related]
10. Intrapleural 'outside-in' gene therapy: therapeutics for organs of the chest via gene transfer to the pleura.
Heguy A; Crystal RG
Curr Opin Mol Ther; 2005 Oct; 7(5):440-53. PubMed ID: 16248279
[TBL] [Abstract][Full Text] [Related]
11. Gene therapy for alpha 1-antitrypsin deficiency with an oxidant-resistant human alpha 1-antitrypsin.
Sosulski ML; Stiles KM; Frenk EZ; Hart FM; Matsumura Y; De BP; Kaminsky SM; Crystal RG
JCI Insight; 2020 Aug; 5(15):. PubMed ID: 32759494
[TBL] [Abstract][Full Text] [Related]
12. Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy.
Brantly ML; Chulay JD; Wang L; Mueller C; Humphries M; Spencer LT; Rouhani F; Conlon TJ; Calcedo R; Betts MR; Spencer C; Byrne BJ; Wilson JM; Flotte TR
Proc Natl Acad Sci U S A; 2009 Sep; 106(38):16363-8. PubMed ID: 19706466
[TBL] [Abstract][Full Text] [Related]
13. The promise of gene therapy for the treatment of alpha-1 antitrypsin deficiency.
Cruz PE; Mueller C; Flotte TR
Pharmacogenomics; 2007 Sep; 8(9):1191-8. PubMed ID: 17924834
[TBL] [Abstract][Full Text] [Related]
14. Efficient hepatic delivery and expression from a recombinant adeno-associated virus 8 pseudotyped alpha1-antitrypsin vector.
Conlon TJ; Cossette T; Erger K; Choi YK; Clarke T; Scott-Jorgensen M; Song S; Campbell-Thompson M; Crawford J; Flotte TR
Mol Ther; 2005 Nov; 12(5):867-75. PubMed ID: 16085464
[TBL] [Abstract][Full Text] [Related]
15. Clinical protocol. Administration of a replication-deficient adeno-associated virus gene transfer vector expressing the human CLN2 cDNA to the brain of children with late infantile neuronal ceroid lipofuscinosis.
Crystal RG; Sondhi D; Hackett NR; Kaminsky SM; Worgall S; Stieg P; Souweidane M; Hosain S; Heier L; Ballon D; Dinner M; Wisniewski K; Kaplitt M; Greenwald BM; Howell JD; Strybing K; Dyke J; Voss H
Hum Gene Ther; 2004 Nov; 15(11):1131-54. PubMed ID: 15610613
[TBL] [Abstract][Full Text] [Related]
16. Survival Advantage of Both Human Hepatocyte Xenografts and Genome-Edited Hepatocytes for Treatment of α-1 Antitrypsin Deficiency.
Borel F; Tang Q; Gernoux G; Greer C; Wang Z; Barzel A; Kay MA; Shultz LD; Greiner DL; Flotte TR; Brehm MA; Mueller C
Mol Ther; 2017 Nov; 25(11):2477-2489. PubMed ID: 29032169
[TBL] [Abstract][Full Text] [Related]
17. Gene therapy for human alpha1-antitrypsin deficiency in an animal model using SV40-derived vectors.
Duan YY; Wu J; Zhu JL; Liu SL; Ozaki I; Strayer DS; Zern MA
Gastroenterology; 2004 Oct; 127(4):1222-32. PubMed ID: 15480999
[TBL] [Abstract][Full Text] [Related]
18. Gene therapy progress and prospects: alpha-1 antitrypsin.
Stecenko AA; Brigham KL
Gene Ther; 2003 Jan; 10(2):95-9. PubMed ID: 12571637
[TBL] [Abstract][Full Text] [Related]
19. [Efficient and durable gene delivery of self complementary adeno-associated virus 6 vector and impact of pre-existing immunity].
Tu L; Sun L; Xue J; Zhang Y; Lu Y
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2012 Dec; 29(6):1150-5. PubMed ID: 23469547
[TBL] [Abstract][Full Text] [Related]
20. Class I-restricted T-cell responses to a polymorphic peptide in a gene therapy clinical trial for α-1-antitrypsin deficiency.
Calcedo R; Somanathan S; Qin Q; Betts MR; Rech AJ; Vonderheide RH; Mueller C; Flotte TR; Wilson JM
Proc Natl Acad Sci U S A; 2017 Feb; 114(7):1655-1659. PubMed ID: 28137880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
